| DXCM |
Report |
Q2 revenue |
BEAT |
pred ~$1.305B vs. cons $1.291B |
MEDIUM |
| DXCM |
Report |
Q2 operating EPS |
BEAT |
pred ~$0.616 vs. cons $0.609 |
MEDIUM |
| DXCM |
Report |
Q2 net new patients |
BEAT |
pred ~152.0K vs. cons 148.2K |
MEDIUM |
| DXCM |
Guide |
FY26 revenue |
UNCHANGED |
guide $5.16B-$5.25B vs. cons $5.224B |
MEDIUM |
| DXCM |
Guide |
FY26 operating margin |
UNCHANGED |
guide 23.0%-23.5% vs. cons UNVERIFIED |
LOW |
| DXCM |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
LOW |
| DXCM |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — implicit H2 revenue caution drives revisions lower |
LOW |